Kwas acetylosalicylowy w profilaktyce pierwotnej i wtórnej chorób układu sercowo-naczyniowego Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2011
Słowa kluczowe:
kwas acetylosalicylowy, profilaktyka pierwotna, profilaktyka wtórna, choroby układu sercowo-naczyniowego
##plugins.themes.bootstrap3.article.main##
Abstrakt
W artykule podsumowano najnowsze zalecenia i dane dotyczące stosowania kwasu acetylosalicylowego w profilaktyce pierwotnej i wtórnej chorób układu krążenia.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
Wilczko , J. (2011). Kwas acetylosalicylowy w profilaktyce pierwotnej i wtórnej chorób układu sercowo-naczyniowego . Kardiologia W Praktyce, 5(4), 164-169. Pobrano z https://www.journalsmededu.pl/index.php/kwp/article/view/1592
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Czyż M., Watała C.: Aspiryna – cudowne panaceum? Molekularne mechanizmy działania kwasu acetylosalicylowego w organizmie. Postępy Hig. Med. Dośw. 2005, 59: 105-115.
2. Zipes D.P., Libby P., Bonow R., Braunwald E. (red.): Braunwald’s Heart Disease – a textbook of cardiovascular medicine. Wyd. 7. Elsevier Saunders Company, Philadelphia 2004.
3. Gollapudi R.R., Teirstein P.S., Stevenson D.D.: Aspirin sensitivity: implications for patients with coronary artery disease. JAMA 2004, 292: 3017-3023.
4. Kawecka-Jaszcz K.: Ocena całkowitego ryzyka sercowo-naczyniowego. Terapia 2005, 7-8: 168-169.
5. Eidelman R.S., Hebert P.R., Weisman S.M., Hennekens C.H.: An Update on Aspirin in the Primary Prevention of Cardiovascular Disease. Arch. Intern. Med. 2003, 163: 2006-2010.
6. Vane J.R.: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 1971, 231: 232-235.
7. Harrington R.A., Becker R.C., Ezekowitz M.: Platelet-Active Drugs: Antithrombotic Therapy for Coronary Artery Disease. Chest 2004, 126: 513S-548S.
8. Quyyumi A.A.: Effects of aspirin on endothelial dysfunction in atherosclerosis. Am. J. Cardiol. 1998, 82: 31S-33S.
9. Pongracz E., Kaposzta Z.: Antiplatelet therapy in ischemic stroke. Expert Rev. Neurother. 2005, 5: 541-549.
10. Kappelle L.J.: Primary prevention of cardiovascular disease with acetylsalicylic acid: in high-risk patients. Ned. Tijdschr. Geneeskd. 2005, 149(16): 853-854.
11. Howard P.A.: Aspirin resistance. Ann. Pharmacother. 2002, 36: 1620-1564.
12. Weber A.A.: Towards a definition of aspirin resistance: a typological approach. Platelets 2002, 1: 37-40.
13. Kuliczkowski W., Halawa B., Korolko B.: Aspirin resistance in ischaemic heart disease. Kardiol. Pol. 2005, 62: 14-25.
14. Patrono C., Coller B., Fitzgerald G.A.: Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects. Chest 2004, 126: 234S-264S.
15. Bolten W.W.: The problem of the atherothrombotic potential of nonsteroidal anti-inflammatory drugs. Ann. Rheum. Dis. 2006, 65: 7-13.
16. Hansson L., Zanchetti A., Carruthers S.G.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351: 1755-1762.
17. Husain S., Andrews N.P., Mulcahy D. et al.: Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 1998, 97: 716-720.
18. Hirsh J.: Aspirin and other platelet-active drugs. The relationship between dose, effectiveness and side effects. Chest 1992, 102(supl.): 327S-336S.
19. ISIS-2 Collaborative Group: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1998, 349: II.
20. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable\ coronary artery disease. Lancet 1990, 336: 827-830.
21. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplateled theraphy. BMJ 2002, 324: 71-86.
22. Pearson T.A., Blair S.N., Daniels S.R. et al.: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Disease. Circulation 2002, 106: 388-391.
23. Albers G.W., Amarenco P., Easton J.D.: Antithrombotic and Thrombolytic Therapy for Ischemic Stroke. Chest 2004, 126: 483S-512S.
24. Patrono C.: Aspirin resistance: definition, mechanisms and clinical read-outs. J. Thromb. Haemost. 2003, 1: 1710-1713.
25. Eikelboom J.W., Hirsh J., Weitz J.I. et al.: Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002, 105: 1650-1655. 26. Mehta S.S., Silver R.J., Aaronson A. et al.: Comparison of Aspirin Resistance in Type 1 Versus Type 2 Diabetes Mellitus. Am. J. Cardiol. 2006, 4(97): 567-570.
2. Zipes D.P., Libby P., Bonow R., Braunwald E. (red.): Braunwald’s Heart Disease – a textbook of cardiovascular medicine. Wyd. 7. Elsevier Saunders Company, Philadelphia 2004.
3. Gollapudi R.R., Teirstein P.S., Stevenson D.D.: Aspirin sensitivity: implications for patients with coronary artery disease. JAMA 2004, 292: 3017-3023.
4. Kawecka-Jaszcz K.: Ocena całkowitego ryzyka sercowo-naczyniowego. Terapia 2005, 7-8: 168-169.
5. Eidelman R.S., Hebert P.R., Weisman S.M., Hennekens C.H.: An Update on Aspirin in the Primary Prevention of Cardiovascular Disease. Arch. Intern. Med. 2003, 163: 2006-2010.
6. Vane J.R.: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 1971, 231: 232-235.
7. Harrington R.A., Becker R.C., Ezekowitz M.: Platelet-Active Drugs: Antithrombotic Therapy for Coronary Artery Disease. Chest 2004, 126: 513S-548S.
8. Quyyumi A.A.: Effects of aspirin on endothelial dysfunction in atherosclerosis. Am. J. Cardiol. 1998, 82: 31S-33S.
9. Pongracz E., Kaposzta Z.: Antiplatelet therapy in ischemic stroke. Expert Rev. Neurother. 2005, 5: 541-549.
10. Kappelle L.J.: Primary prevention of cardiovascular disease with acetylsalicylic acid: in high-risk patients. Ned. Tijdschr. Geneeskd. 2005, 149(16): 853-854.
11. Howard P.A.: Aspirin resistance. Ann. Pharmacother. 2002, 36: 1620-1564.
12. Weber A.A.: Towards a definition of aspirin resistance: a typological approach. Platelets 2002, 1: 37-40.
13. Kuliczkowski W., Halawa B., Korolko B.: Aspirin resistance in ischaemic heart disease. Kardiol. Pol. 2005, 62: 14-25.
14. Patrono C., Coller B., Fitzgerald G.A.: Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects. Chest 2004, 126: 234S-264S.
15. Bolten W.W.: The problem of the atherothrombotic potential of nonsteroidal anti-inflammatory drugs. Ann. Rheum. Dis. 2006, 65: 7-13.
16. Hansson L., Zanchetti A., Carruthers S.G.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351: 1755-1762.
17. Husain S., Andrews N.P., Mulcahy D. et al.: Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 1998, 97: 716-720.
18. Hirsh J.: Aspirin and other platelet-active drugs. The relationship between dose, effectiveness and side effects. Chest 1992, 102(supl.): 327S-336S.
19. ISIS-2 Collaborative Group: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1998, 349: II.
20. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable\ coronary artery disease. Lancet 1990, 336: 827-830.
21. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplateled theraphy. BMJ 2002, 324: 71-86.
22. Pearson T.A., Blair S.N., Daniels S.R. et al.: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Disease. Circulation 2002, 106: 388-391.
23. Albers G.W., Amarenco P., Easton J.D.: Antithrombotic and Thrombolytic Therapy for Ischemic Stroke. Chest 2004, 126: 483S-512S.
24. Patrono C.: Aspirin resistance: definition, mechanisms and clinical read-outs. J. Thromb. Haemost. 2003, 1: 1710-1713.
25. Eikelboom J.W., Hirsh J., Weitz J.I. et al.: Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002, 105: 1650-1655. 26. Mehta S.S., Silver R.J., Aaronson A. et al.: Comparison of Aspirin Resistance in Type 1 Versus Type 2 Diabetes Mellitus. Am. J. Cardiol. 2006, 4(97): 567-570.